KMDA Q4 2021 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$520M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$31M-0.2% YoY

Gross Profit

$7M21.0% margin

Operating Income

-$3M-10.5% margin

Net Income

-$5M-15.9% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+36.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$25,000

Balance Sheet

Total Assets

$319M

Total Liabilities

$142M

Stockholders' Equity

$177M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$32M	-0.2%
Gross Profit	$7M	$10M	-35.1%
Operating Income	-$3M	$3M	-224.7%
Net Income	-$5M	$2M	-407.5%

Geographic Segments

OtherForeignCountriesThreeMember

$5M99%

OtherCountriesMember

$53,0001%